Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported revenue of $4.02B, down 0.9% year over year. Operating margin was 0.6% and net margin -3.6%, on a free-cash-flow margin of 12.9% with capital expenditure at 5.5% of revenue. Every figure is computed directly from CRL's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $4.02B | 0.6% | -3.6% |
| FY2024 | $4.05B | 5.6% | 0.5% |
| FY2023 | $4.13B | 14.9% | 11.5% |
| FY2022 | $3.98B | 16.4% | 12.2% |
| FY2021 | $3.54B | 16.7% | 11.0% |
How does CRL compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 23 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: IQV · ACM · BAH · ICLR · PAYX · IT
See CRL benchmarked against two sector peers (free) →
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.